{"DataElement":{"publicId":"3762327","version":"1","preferredName":"Breast Carcinoma Residual Disease Overall Cellularity Percentage Value","preferredDefinition":"Numeric entry to represent the estimated percent of the final primary tumor bed that contains residual cancer that is different from the options given.","longName":"3371429v1.0:3028685v1.0","context":"BOLD","contextVersion":"1","DataElementConcept":{"publicId":"3371429","version":"1","preferredName":"Breast Carcinoma Residual Disease Overall Cellularity","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002_Cancer cells that remain after attempts to remove the cancer have been made._Including everything._The degree, quality, or condition of cells that are present. (On-line Medical Dictionary)","longName":"3243669v1.0:3371427v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3243669","version":"1","preferredName":"Breast Carcinoma Residual Disease","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002:Cancer cells that remain after attempts to remove the cancer have been made.","longName":"C4872:C4809","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Residual Disease","conceptCode":"C4809","definition":"Tumor cells that remain in the body following cancer treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A55DCBB1-76DC-F00A-E040-BB89AD431D27","latestVersionIndicator":"Yes","beginDate":"2011-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-06-10","modifiedBy":"ONEDATA","dateModified":"2011-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3371427","version":"1","preferredName":"Overall Cellularity","preferredDefinition":"Including everything.:The degree, quality, or condition of cells that are present. (On-line Medical Dictionary)","longName":"C25605:C37923","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Overall","conceptCode":"C25605","definition":"Including everything.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cellularity","conceptCode":"C37923","definition":"The degree, quality, or condition of cells that are present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8606DF3-AC9A-79F6-E040-BB89AD433880","latestVersionIndicator":"Yes","beginDate":"2012-02-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-07","modifiedBy":"ONEDATA","dateModified":"2012-02-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008547","version":"1","preferredName":"Specimen Characteristics","preferredDefinition":"attributes of a patient's laboratory sample, including the source, condition, and fixative.","longName":"SPEC_CHAR","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22908C4-638F-4A74-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8606DF3-ACAB-79F6-E040-BB89AD433880","latestVersionIndicator":"Yes","beginDate":"2012-02-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-07","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3028685","version":"1","preferredName":"Cell Characteristic Percentage Value","preferredDefinition":"values for the percentage for measurement of a trait of a specimen of tumor or other tissue._The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid._The distinguishing qualities or prominent aspect of a person, object, action, process, or substance._Percentage; a fraction or ratio with 100 understood as the denominator.","longName":"CELL_CHAR_PCT_VAL","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","unitOfMeasure":"%","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":"0","PermissibleValues":[],"ConceptualDomain":{"publicId":"2178079","version":"1","preferredName":"Specimen Characteristics","preferredDefinition":"attributes of a patient's laboratory sample, including the source, condition, and fixative.","longName":"SPEC_CHAR","context":"EDRN","contextVersion":"1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"CC049DE1-E986-5FB4-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3028684","version":"1","preferredName":"Cell Characteristic Percentage Value","preferredDefinition":"The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.:Characteristics; distinguishing qualities of a person, object, or substance.:Percentage; a fraction or ratio with 100 understood as the denominator.:Value; a numerical quantity measured or assigned or computed.","longName":"C12508:C25447:C25613:CL052797","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cell","conceptCode":"C12508","definition":"The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Characteristic","conceptCode":"C25447","definition":"The distinguishing qualities or prominent aspect of a person, object, action, process, or substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Value","conceptCode":"CL052797","definition":"Value; a numerical quantity measured or assigned or computed.","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"825FF8E4-2232-6783-E040-BB89AD43233B","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ONEDATA","dateModified":"2010-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"825FF8E4-2243-6783-E040-BB89AD43233B","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ONEDATA","dateModified":"2010-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3461586","version":"1","longName":"BOLD:Breast Oncology Local Disease","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3461587","version":"1","longName":"Preoperative Elements","context":"NCIP"}]},{"publicId":"3886755","version":"1","longName":"Preoperative Elements","context":"BOLD","ClassificationSchemeItems":[{"publicId":"3902140","version":"1","longName":"Preoperative","context":"BOLD"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Other (%)","type":"Preferred Question Text","description":"Other (%)","url":null,"context":"NCIP"}],"origin":"BOLD:Breast Oncology Local Disease Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"DCC460A2-D205-D946-E040-BB89AD432A72","latestVersionIndicator":"Yes","beginDate":"2013-05-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-15","modifiedBy":"REEVESD","dateModified":"2016-09-06","changeDescription":"Curated to support Breast Oncology Local Disease (BOLD) Initiative","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}